Clinical trial
Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme
NCT00005826 · European Organisation for Research and Treatment of Cancer - EORTC, Other · Completed
Key facts
| NCT number | NCT00005826 |
|---|---|
| Title | Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme |
| Official title | Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) Administered as a "5 Days On-2 Days Off" Oral Treatment in Glioblastoma Multiforme |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | rubitecan |
| Enrollment | 17 |
| Start date | Mar 1, 2000 |
| Primary completion | Sep 1, 2000 |
| First posted | Jun 18, 2004 |
| Last update posted | Sep 24, 2012 |
| Countries | Belgium, France, Italy, Netherlands, Spain, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: